
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2017

AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

001-37487
(Commission File Number)

13-3632859
(IRS Employer
Identification Number)

9635 Granite Ridge Drive, Suite 100
San Diego, California
(Address of principal executive offices)

92123
(Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

Today, at 3:00 PM, New York time, James Joyce, CEO, of Aethlon Medical, Inc. will be making a presentation at the 2017 Rodman & Renshaw 19th Annual Global Investment Conference. A copy of the presentation is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS

EXHIBIT NO. DESCRIPTION

99.1 [Presentation materials – Rodman & Renshaw 19th Annual Global Investment Conference, September 11, 2017](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: September 11, 2017

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	<u>Presentation materials – September 11, 2017</u>




Image of Ebola viruses exiting host cells - Courtesy of NIAID

RODMAN & RENSHAW CONFERENCE

JIM JOYCE - CHAIRMAN, CEO
NASDAQ - AEMD / SEPTEMBER 11, 2017



FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

TO ADDRESS UNMET NEEDS
IN GLOBAL HEALTH & BIODEFENSE

MISSION

TO SAVE LIVES

JR LEAD THERAPEUTIC CANDIDATE



A FIRST-IN-CLASS THERAPEUTIC TECHNOLOGY TO BE ADVANCED THROUGH THE FDA

THE HEMOPURIFIER®

A BROAD-SPECTRUM VIRUS TREATMENT
CANDIDATE

DESIGNED FOR THE SINGLE-USE REMOVAL OF INFECTIOUS VIRUSES FROM
BLOOD



FDA EXPEDITED ACCESS PATHWAY PROGRAM SUBMISSION

- WE SUBMITTED AN EXPEDITED ACCESS PATHWAY (EAP) PROGRAM SUBMISSION TO THE FDA ON AUGUST 11, 2017
- THE FDA ESTABLISHED THE EXPEDITED ACCESS PATHWAY (EAP) PROGRAM FOR SELECT MEDICAL DEVICES THAT DEMONSTRATE THE POTENTIAL TO ADDRESS LIFE-THREATENING OR IRREVERSIBLY DEBILITATING, UNMET MEDICAL NEEDS
- AN OBJECTIVE OF THE EAP PROGRAM IS TO HELP PATIENTS HAVE MORE TIMELY ACCESS TO EAP DESIGNATED MEDICAL DEVICES BY EXPEDITING THEIR DEVELOPMENT, ASSESSMENT AND REVIEW

THE AETHLON HEMOPURIFIER®



THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS DESIGNATED THE AETHLON HEMOPURIFIER® TO THE EXPEDITED ACCESS PATHWAY (EAP) PROGRAM RELATED TO THE TREATMENT OF LIFE-THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH AN APPROVED THERAPY

INFECTIOUS HUMAN VIRUSES

A SIGNIFICANT UNMET NEED IN GLOBAL HEALTH & BIODEFENSE

~300 VIRUSES ARE INFECTIOUS TO HUMANS

ONLY 9 ARE ADDRESSED WITH AN APPROVED ANTIVIRAL DRUG AGENT

JUST 1 OF 13 CATEGORY "A" VIRUSES ARE ADDRESSED WITH A TREATMENT COUNTERMEASURE IN THE STRATEGIC NATIONAL STOCKPILE

3-4 NEW HUMAN VIRUSES ARE IDENTIFIED EACH YEAR*

GLOBAL WARMING, URBAN CROWDING AND TRANSCONTINENTAL TRAVEL ARE FUELING AN INCREASED EMERGENCE OF PANDEMIC VIRUS OUTBREAKS

NO ANTIVIRAL STRATEGY TO ADDRESS VIRUSES ENGINEERED BY MAN AS AGENTS OF BIOTERRORISM

** Center for Immunity and Evolution, University of Edinburgh*

*" A GENETICALLY ENGINEERED VIRUS COULD KILL MORE PEOPLE
THAT NUCLEAR WEAPONS - AND YET NO COUNTRY ON EARTH IS
READY FOR THE THREAT"*

*BILL GATES
MUNICH SECURITY CONFERENCE
FEBRUARY 18, 2017*

HEMOPURIFIER® ATTRIBUTES

RETHINKING THE TREATMENT OF VIRAL PATHOGENS


STRUCTURE-SPECIFIC NOT
DISEASE-SPECIFIC MECHANISM OF ACTION

GLYCAN SHIELD (THE IMMUNE
CLOAK) CAPTURE MECHANISM

ELIMINATES HIGHLY
GLYCOSYLATED VIRUSES FROM THE
ENTIRE CIRCULATORY SYSTEM

COMPANION ASSAY REINFORCES
MECHANISM PERFORMANCE

DEPLOYED ON AN ESTABLISHED
GLOBAL INSTRUMENT NETWORK



*Image of HIV glycan shield in green
Courtesy of Oxford University*

THE AETHLON HEMOPURIFIER®

FROM THEORETICAL CONCEPT TO CLINICAL REALITY



- ☑ >16 *IN VITRO* VIRUS CAPTURE STUDIES
- ☑ FOUR INVESTIGATIONAL HUMAN STUDIES (OUTSIDE U.S.)
- ☑ RECENTLY CONCLUDED AN FDA APPROVED HUMAN FEASIBILITY STUDY
- ☑ RECEIVED EXPEDITED ACCESS PATHWAY (EAP) DESIGNATED FROM THE FDA

GOAL OF OUR EAP PROGRAM SUBMISSION

- TO ACCELERATE THE REGULATORY ADVANCEMENT OF OUR HEMOPURIFIER®
- TO ESTABLISH THE COMMERCIALIZATION PATHWAY AGAINST LIFE-THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH APPROVED THERAPIES
- TO DEMONSTRATE THAT **FDA** WILL ALLOW OUR PRODUCT "INDICATION OF USE" TO BE STRUCTURE-SPECIFIC VS. A DISEASE-SPECIFIC



The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has received the above submission dated August 11, 2017, including your request for Expedited Access Pathway (EAP) designation. The proposed indications for use includes "The Hemopurifier is a single-use device indicated for the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment." We are pleased to inform you that your combination product and proposed indication for use meets the criteria and has been granted EAP designation.

HEMOPURIFIER® CAPTURE VALIDATIONS OF HIGHLY GLYCOSYLATED VIRUSES

Bioterror & Pandemic Threat Viruses

- ☑ Ebola (CDC, USAMRIID & Human Experience)
- ☑ Lassa (Southwest Foundation for Biomedical Research)
- ☑ MERS-CoV (Goethe University Research Institute)
- ☑ Smallpox (Battelle Memorial Research Institute)
(based on Monkeypox & Vaccinia models)



Hemopurifier® in vitro capture validations

Mosquito-Borne Viruses


- ☑ Chikungunya (National Institute of Virology)
- ☑ Dengue (National Institute of Virology)
- ☑ West Nile (Battelle Memorial Research Institute)
- ☑ Zika (Aethlon Research Team)



Pandemic Influenza Viruses


- ☑ H1N1 Swine Flu (Aethlon Research Team)
- ☑ H5N1 Bird Flu (Battelle Memorial Research Institute)
- ☑ Spanish Flu of 1918-R (Battelle MRI)


Actual Spanish Flu of 1918 pandemic resulted in approximately 50 million deaths worldwide.



Chronic & Latent Viruses

- ☑ Human Immunodeficiency Virus (Aethlon Research Team & Human Treatment Outcomes)
- ☑ Hepatitis C Virus (Aethlon Research Team & Human Treatment Outcomes)
- ☑ Cytomegalovirus (DOD-DARPA)
- ☑ Epstein-Barr Virus (DOD-DARPA)
- ☑ Herpes Simplex Virus-1 (DOD-DARPA)





Ebola Image Courtesy of NIAID

THE TREATMENT OF EBOLA VIRUS

A CASE STUDY AGAINST A LIFE-THREATENING HIGHLY
GLYCOSYLATED VIRUS WITHOUT AN APPROVED THERAPY



THE TREATMENT OF EBOLA VIRUS



A SINGLE 6.5-HOUR
ADMINISTRATION OF HEMOPURIFIER®
THERAPY WAS DELIVERED TO THE
PATIENT, WHO WAS COMATOSE WITH
MULTIPLE ORGAN FAILURE.

EBOLA TREATMENT RESULTS

PRESENTED AT THE AMERICAN SOCIETY OF NEPHROLOGY ANNUAL MEETING BY
HELMUT GEIGER, M.D., CHIEF OF NEPHROLOGY AT FRANKFURT UNIVERSITY
HOSPITAL

- HEMOPURIFIER® THERAPY WAS WELL TOLERATED WITH NO ADVERSE EVENTS
- PRE-TREATMENT VIRAL LOAD PRIOR WAS MEASURED TO BE 400,000 COPIES/ML
- POST-TREATMENT VIRAL LOAD WAS MEASURED AT 1,000 COPIES/ML
- PATIENT MADE A FULL RECOVERY

THE TREATMENT OF EBOLA VIRUS

DR. STEFAN BÜTTNER
HOLDING THE HEMOPURIFIER® AFTER
TREATMENT



VIRUS CAPTURE ASSAY RESULT

242 MILLION COPIES OF EBOLA
VIRUS CAPTURED WITHIN THE
HEMOPURIFIER® DURING THE 6.5
HOUR TREATMENT



Analysis: BSL4 Lab
Philipps University Marburg
(O. Dolnik/M. Eickmann/S. Becker)

Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease - First Experience with Lectin Affinity Plasmapheresis

[Buttner S.a](#) · Koch B.a · Dolnik O.b · Eickmann M.b · Freiwald T.a · Rudolf S.a · Engel J.a · Becker S.b · Ronco C.c · Geiger H.a
[Author affiliations](#)

[Corresponding Author](#)

Keywords: [Ebola virus](#) [Glycoprotein](#) [Lectin affinity](#) [Plasmapheresis](#)

February 2015

Abstract

Therapeutic options for Ebola virus disease (EVD) are currently limited to (1) best supportive care, and (2) evolving virus-specific therapies, resulting from decades of analyzing one of the world's deadliest diseases. Supportive care ranges from oral or intravenous rehydration therapy and anti-emetics in developing countries to much more extensive life-support interventions in resource-rich countries. Current EVD-specific therapies attempt to either interfere with the earliest steps of viral replication or to elicit a strong immune response against the virus. An entirely new approach is the extracorporeal elimination of viruses and viral glycoproteins by lectin affinity plasmapheresis. Herein, we report for the first time the successful and safe use of lectin affinity plasmapheresis in a patient with severe Ebola virus disease.

A LEADING CANDIDATE TO TREAT LIFE-THREATENING
VIRUSES THAT ARE NOT ADDRESSED WITH ANTIVIRAL
DRUGS



A LEADING CANDIDATE TO FULFILL U.S. GOVERNMENT INITIATIVES
TO PROTECT CITIZENS FROM BIOTERROR & PANDEMIC THREATS

2016 Public Health Emergency Medical Countermeasures
Enterprise (PHEMCE) Strategy and Implementation Plan



THE AETHLON HEMOPURIFIER®

ALIGNS TO MEET 5 DIFFERENT PHEMCE OBJECTIVES



MEETING THE PHEMCE OBJECTIVES

PHEMCE goal is to procure medical countermeasures (MCMs)
for the strategic national stockpile

- ☑ PHEMCE seeks broad-spectrum MCMs that address high-priority threats and also have commercial viability in other medical applications
- ☑ Broad-spectrum approach to address both known and unknown threats
- ☑ Broad-spectrum MCM against emerging threats, including Ebola, Zika and MERS-CoV
- ☑ MCM against pandemic influenza, including non-pharmaceutical MCMs
- ☑ MCMs for at-risk children, pregnant women and older adults for whom first line treatment countermeasures are not recommended



NEXT STEPS

LEVERAGE EAP PATHWAY DESIGNATION TO ESTABLISH
COMMERCIALIZATION PATHWAY FOR VIRUSES THAT ARE;

- LIFE-THREATENING
- HIGHLY-GLYCOSYLATED
- NOT ADDRESSED WITH AN APPROVED THERAPY
- AND, HAVE BEEN VALIDATED TO BE CAPTURED BY THE AETHLON HEMOPURIFIER®

NEXT STEPS

CONTINUED

- EXPAND HEMOPURIFIER® PRODUCTION CAPABILITIES
- ADVANCE THE HEMOPURIFIER® TO FULFILL U.S. GOVERNMENT PHEMCE OBJECTIVES
 - GOAL IS THE STRATEGIC NATIONAL STOCKPILE
- ADVANCE RESEARCH PROGRAMS AGAINST OTHER GLYCOSYLATED DISEASE TARGETS
 - TUMOR-DERIVED EXOSOMES
 - NEUROLOGICAL TAUOPATHY ASSOCIATED EXOSOMES
- ADVANCE EXOSOME BIOMARKER PROGRAMS TO DIAGNOSE AND MONITOR CANCER AND TAUOPATHY TREATMENT TARGETS



Focused on diagnosing
diseases that are current
or future therapeutic
targets for Aethlon
Medical



80% Owned by Aethlon Medical

Preparing to launch follow-on study to diagnose Chronic Traumatic Encephalopathy in the living



TO ADDRESS UNMET NEEDS
IN GLOBAL HEALTH & BIODEFENSE

THE AETHLON HEMOPURIFIER®



THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS DESIGNATED THE AETHLON HEMOPURIFIER® TO THE EXPEDITED ACCESS PATHWAY (EAP) PROGRAM RELATED TO THE TREATMENT OF LIFE-THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH AN APPROVED THERAPY

MISSION

TO SAVE LIVES



9635 Granite Ridge Drive, Suite 100

San Diego, California 92123

858.459.7800

Nasdaq: AEMD

www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com